Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repaymentsWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Issuances (2018 - 2025)

BridgeBio Pharma recorded quarterly Long-Term Debt Issuances of -$575.0 million in Q4 2025, down 200.0% quarter-over-quarter from $575.0 million in Q3 2025.

BridgeBio Pharma's Long-Term Debt Issuances history runs 5 years deep, the most recent figure standing at -$575.0 million for Q4 2025.

  • In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$575.0 million; the TTM figure through Sep 2025 stood at $575.0 million (changed N/A YoY), while the FY2021 annual figure was $456.3 million, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at -$575.0 million for Q4 2025 at BridgeBio Pharma, down from $575.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $747.5 million in Q1 2021 to a low of -$722.5 million in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 2.73 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 BridgeBio Pharma 12.91 Bn 11.98 Bn 184.58 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -575.00 Mn
Dec 31, 2025 -575.00 Mn
Sep 30, 2025 575.00 Mn
Sep 30, 2025 575.00 Mn
Dec 31, 2021 431.30 Mn
Dec 31, 2021 431.30 Mn
Jun 30, 2021 -722.50 Mn
Jun 30, 2021 -722.50 Mn
Mar 31, 2021 747.50 Mn
Mar 31, 2021 747.50 Mn
Dec 31, 2020 -550.00 Mn
Dec 31, 2020 -550.00 Mn
Mar 31, 2020 550.00 Mn
Mar 31, 2020 550.00 Mn
Dec 31, 2019 17.15 Mn
Dec 31, 2019 17.15 Mn
Dec 31, 2018 -35.59 Mn
Dec 31, 2018 -35.59 Mn